|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Additional
Studies: Bapineuzumab and Active Immunotherapeutic
Conjugate
In addition to the intravenous formulation of bapineuzumab, a
subcutaneous formulation of this antibody is in Phase 2 clinical
trials. There are a number of
back-up
compounds to both bapineuzumab and ACC-001 in the preclinical
phase of development.
|
| |||||||